Please wait a minute...
Reviews in Cardiovascular Medicine  2018, Vol. 19 Issue (S1): 20-24     DOI: 10.3909/ricm19S1S0003
Review Previous articles | Next articles
Can We Cure Atherosclerosis?
Jennifer G. Robinson1, Michael H. Davidson2
1 Departments of Epidemiology & Medicine, University of Iowa College of Public Health and Carver College of Medicine, Iowa City, IA
2 Department of Cardiology, University of Chicago Medicine, Chicago, IL
Download:  PDF(774KB)  ( 214 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Cardiovascular disease mortality rates have begun to rise in the United States. Based on the large body of supportive evidence, we propose a proof-of-concept, first-in-human trial to cure atherosclerosis: CURing Early ATHEROsclerosis (CURE ATHERO). This trial is based on a model of intensive induction therapy for extensive, if not complete, plaque regression, followed by intermittent maintenance therapy. An extensive body of evidence has demonstrated the causal role of apolipoprotein B lipoproteins in atherosclerosis progression and data suggest intensive low-density lipoprotein cholesterol (LDL-C) lowering may have a substantial impact on earlier stages of atherosclerosis. Compared with lifetime treatment to prevent atherosclerosis progression, this induction–intermittent treatment model will minimize costs and maximize adherence and safety.
Key words:  Atherosclerosis      Regression      Primary prevention      Familial hypercholesterolemia      Apolipoprotein B lipoproteins      PCSK9 monoclonal antibodies      Statins     
Published:  20 January 2018     

Cite this article: 

Jennifer G. Robinson, Karol E. Watson. Can We Cure Atherosclerosis?. Reviews in Cardiovascular Medicine, 2018, 19(S1): 20-24.

URL: 

https://rcm.imrpress.com/EN/10.3909/ricm19S1S0003     OR     https://rcm.imrpress.com/EN/Y2018/V19/IS1/20

[1] Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017; 135: e146-e603.
[2] Robinson JG, Gidding SS. Curing atherosclerosis should be the next major cardiovascular prevention goal. J Am Coll Cardiol. 2014; 63(25 Pt A): 2779-2785.
[3] Insull W Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 2009; 122(1 suppl 1): S3-S14.
[4] Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016; 27: 473-483.
[5] Ference BA, Ginsberg HN, Graham I, et al. Lowdensity lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38: 2459-2472.
[6] Tabas I. 2016 Russell Ross Memorial Lecture in Vascular Biology: molecular-cellular mechanisms in the progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2017; 37: 183-189.
[7] Fisher EA. Regression of atherosclerosis: the journey from the liver to the plaque and back. Arterioscler Thromb Vasc Biol. 2016; 36: 226-235.
[8] Björkegren JLM, Hägg S, Talukdar HA, et al. Plasma cholesterol–induced lesion networks activated before regression of early, mature, and advanced atherosclerosis. PLoS Genet. 2014; 10: e1004201.
[9] Williams KJ, Feig JE, Fisher EA. Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med. 2008; 5: 91-102.
[10] McMahan CA, Gidding SS, Malcom GT, et al; Pathobiological Determinants of Atherosclerosis in Youth Research Group. Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis. Pediatrics. 2006; 118: 1447-1455.
[11] Webber BJ, Seguin PG, Burnett DG, et al. Prevalence of and risk factors for autopsy-determined atherosclerosis among US service members, 2001-2011. JAMA. 2012; 308: 2577-2583.
[12] Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376: 1670-1681.
[13] Cannon CP, Blazing MA, Giugliano RP, et al; IMPROVE- IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387-2397.
[14] Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376: 1713-1722.
[15] Robinson JG, Farnier M, Krempf M, et al; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372: 1489-1499.
[16] Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016; 388: 2532-2561.
[17] Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statintreated patients: the glagov randomized clinical trial. JAMA. 2016; 316: 2373-2384.
[18] Giugliano RP, Wiviott SD, Blazing MA, et al. Longterm safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol. 2017; 2: 547-555.
[19] Giugliano RP, Keech A, Murphy SA, et al. Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: Secondary analysis of patients with low ldl cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial. JAMA Cardiol. 2017; 2: 1385-1391.
[20] Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380: 581-590.
[21] Robinson JG. Starting primary prevention earlier with statins. Am J Cardiol. 2014; 114: 1437-1442.
[22] Packard CJ, Ford I. Long-term follow-up of lipid lowering trials. Curr Opin Lipidol. 2015; 26: 572-579.
[23] Navar-Boggan AM, Peterson ED, D’Agostino RB Sr, et al. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation. 2015; 131: 451-458.
[24] Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005; 37: 161-165.
[25] Gidding SS, Ann Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015; 132: 2167-2192.
[26] Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016; 67: 2578-2589.
[27] Perak AM, Ning H, de Ferranti SD, et al. Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotypeclinical perspective. Circulation. 2016; 134: 9-19.
[28] Amor-Salamanca A, Castillo S, Gonzalez-Vioque E, et al. Genetically confirmed familial hypercholesterolemia in patients with acute coronary syndrome. J Am Coll Cardiol. 2017; 70: 1732-1740.
[29] Nordestgaard BG, Chapman MJ, Humphries SE, et al; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34: 3478-3490.
[30] Kastelein JJ, Hovingh GK, Langslet G, et al. Efficacy and safety of the proprotein convertase subtilisin/ kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017; 11: 195.e4-203.e4.
[1] Michele Provenzano, Giuseppe Coppolino, Teresa Faga, Carlo Garofalo, Raffaele Serra, Michele Andreucci. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer[J]. Reviews in Cardiovascular Medicine, 2019, 20(4): 209-220.
[2] Hao Ding, Ying Zhang, Yujia Liu, Zhilin Liu, Chunxun Shi, Nie Zhichao, Chen Zhehua, Zeng Yanjun. Simulated coronary arterial hemodynamics of myocardial bridging[J]. Reviews in Cardiovascular Medicine, 2019, 20(4): 273-280.
[3] Jin Wang, Xu Geng, Jinghua Sun, Shuquan Zhang, Wenqian Yu, Xueling Zhang, Haixia Liu. The risk of periodontitis for peripheral vascular disease: a systematic review[J]. Reviews in Cardiovascular Medicine, 2019, 20(2): 81-89.
[4] Jennifer G. Robinson, Karol E. Watson. Identifying Patients for Nonstatin Therapy[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 1-8.
[5] Seth J. Baum, Alan S. Brown. Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 25-30.
[6] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31-46.
[7] Jane I. Won, Jun Zhang, Kristen M. Tecson , Peter A. McCullough. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2017, 18(1): 21-28.
[8] Seth J. Baum, Daniel Soffe, P. Barton Duell. Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2016, 17(1-2): 16-27.
[9] Prakash Suryanarayana, Shubha Kollampare, Mohammad Reza Movahed. Anomalous Origin of the Right Coronary Artery From the Left Anterior Descending Artery With Anomalous Course Between the Great Vessels: A Case for Conservative Management With Review of the Literature[J]. Reviews in Cardiovascular Medicine, 2015, 16(3): 221-224.
[10] Mehrnoosh Hashemzadeh, Joseph M. Arreguin, Tyler Roberts, Mohammad Reza Movahed. A Novel Inhibitor of Protease-activated Receptor 1: A Review of Chemical Structure and Mode of Action[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 68-73.
[11] Norman E. Lepor, Laurn Contreras, Chirag Desai, Dean J. Kereiakes. The Potential Role of Anti-PCSK9 Monoclonal Antibodies in the Management of Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 290-309.
[12] Emil M. deGoma. Lomitapide for the Management of Homozygous Familial Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2014, 15(2): 109-118.
[13] Peter P. Toth, Prediman K. Shah, Michael J. Wilkinson, Michael H. Davidson, Peter A. McCullough. Use of Microsomal Triglyceride Transfer Protein Inhibitors in Patients With Homozygous Familial Hypercholesterolemia: Translating Clinical Trial Experience Into Clinical Practice[J]. Reviews in Cardiovascular Medicine, 2014, 15(1): 1-10.
[14] Firas E. Zahr, Suresh R. Mulukutla, Oscar C. Marroquin. A Contemporary Overview of the Pathophysiology of Angina Pectoris[J]. Reviews in Cardiovascular Medicine, 2013, 14(S1): 3-10.
[15] Vitalie Crudu, J. Dawn Abbott. Current Management of Stable Angina Pectoris[J]. Reviews in Cardiovascular Medicine, 2013, 14(S1): 11-22.
No Suggested Reading articles found!